Products
The YM BioSciences pipeline is oncology-focused and aims to develop products for patients with cancer and cancer-related disorders. The investigational products in this pipeline are still in development. In some cases efficacy and safety have not yet been determined.
-
Indication: Cancer
-
Monoclonal antibody
-
Ongoing Phase I, Phase II and Phase III clinical studies for lung cancer, pediatric and adult brain cancer, esophageal cancer, pancreatic cancer, prostate cancer, gastric cancer, cervical cancer, hepatic carcinoma and breast cancer
-
Approved for sale in certain countries
- Indication: Hematological disorders known as myeloproliferative neoplasms (MPNs), also known as myeloproliferative disorders
- JAK 1/2 small molecule inhibitor
- Ongoing Phase I/II clinical study
- Indication: Cancer
- Vascular Disrupting Agent (VDA)
- Ongoing Phase I/II clinical study
-
Indication: Moderate to severe acute pain
-
Inhaled-delivery composition of free and liposome-encapsulated fentanyl
-
Phase II clinical studies completed
-
Phase III clinical studies planned